Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.

Slides:



Advertisements
Similar presentations
Diffusion-Weighted Imaging in Magnetic Resonance Imaging for prostate gland in Malaysian males with high prostate specific antigen in the diagnosis of.
Advertisements

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; cases a year; million population;
Comparative Pathology of TRUS Biopsy, Mapping Biopsy and Prostatectomy Specimens Francisco G. La Rosa, MD Associate Professor,
DIAGNOSI E STADIAZIONE DEL CARCINOMA PROSTATICO Maurizio Brausi Direttore Urologia Ausl Modena Chairman ESOU Director Prostate Cancer Unit.
THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.
Prostate Cancer Detection in Men with an Initial Diagnosis of Atypical small Acinar Proliferations Dr Charles Chabert The Wollongong Hospital.
A re-audit of Prostate biopsies from January to December 2010 and Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees.
Prostate Cancer Genetics and Diagnosis
Pathology Journal Reading
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
Geriatric Health Maintenance: Cancer Screening Linda DeCherrie, MD Geriatric Fellow Mount Sinai Hospital.
Faculty of Medicine - Benha University
Prostate Cancer Education Seminar. What is the Prostate? A male sex gland The size of a walnut below the bladder and in front of the rectum Produces the.
FINE - NEEDLE ASPIRATION BIOPSY By Dr. Tarek Atia.
Understanding the Importance of Prostate Health Middle aged men
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System.
Modern Management of Prostate Cancer With Active Surveillance PROSTATE CANCER SYMPOSIUM NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE SEPTEMBER 10,
Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST.
Male Reproductive System Pathology By Sh.M.D.. The markedly enlarged prostate seen here has not only large lateral lobes, but a very large median lobe.
Prostate Cancer Prostate cancer is the most common cancer detected in American men. The lifetime risk of a 50-year-old man for latent CaP is 40%; for.
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
A GENERAL OVERVIEW OF PROSTATE CANCER. PROSTATE CANCER 101 SPONSORED BY THE CALIFORNIA STATE PROSTATE CANCER COALITION AND THE NATIONAL ALLIANCE OF STATE.
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
Routine PSA: Evaluating the Evidence Sheldon Greenfield, MD Health Policy Research Institute University of California, Irvine October 23, 2012.
MRI-Ultrasound Fusion-Guided Biopsy of the Prostate: Results of Initial Experience in a Radiation Oncology Department Department of Radiation Oncology.
Prostate Pathology Emad Raddaoui, MD, FCAP, FASC.
Prevention with Finasteride Ian M. Thompson, MD October, 2009.
Pathology Reports Nicole Draper, MD.
POTENTIAL FOR FAILURE OF FOCAL PROSTATE HEMI-ABLATION STRATEGIES PG O’Malley 1, B Al Hussein Al Awamlh 1, AM Sarkisian 1, DP Nguyen 1, S Jin 1, R Lee 1,
Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.
Sandy Jones Public Health Advisor Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion April.
Prostate Pathology. Prostate weighs 20 grams in normal adult Retroperitoneal organ,encircling the neck of bladder and urethra Devoid of a distinct capsule.
BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.
بسم الله الرحمن الرحيم. The role of three dimensional transrectal ultrasonography (3-D TRUS) and power Doppler sonography in prostatic lesions evaluation.
Prostate Cancer Management: A Guide for Patients and Caregivers
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Upon completion of this lesson, you will be able to: Identify different diagnostic procedures for breast cancer screening Describe different diagnostic.
This material is protected by United States copyright law, and includes content owned by Discovery Education, The Val Skinner Foundation, and Rutgers,
Understanding Prostate Myths
HIFU AND CRYOSURGERY David Spellberg M.D., FACS.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Assessing Quality of Pathology Reporting: The Case of Tongue Cancer Lihua Liu 1, PhD Wesley Y. Naritoku 2, MD, PhD Juanjuan Zhang 1, MS Lenard Berglund.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
THE PROSTATE. NORMAL PROSTATE FIBROMUSCU – LAR stroma Glands with EPITHELIUM and BASAL CELLS.
IP integration of pathology and histology Lija Joseph MD.
Ultrasound breast core needle biopsy
#4826 Cancer/testis antigen expression pattern is a potential biomarker for prostate cancer aggressiveness Luciane T. Kagohara1, Prakash Kulkarni1, Takumi.
Prostate Cancer Screening in the fit Chilean Elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate.
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Informational Needs During Active Surveillance for Prostate Cancer:
Genomics and Genetic Testing
Urologist’s Impact on Extended Needle Core Prostate Biopsy Histopathologic Variables within a Single Institution Kashika G. Goyal B.S.1, Joshua J. Ebel.
2017 USPSTF Draft Recommendations for Prostate Cancer Screening
CONVERSATIONS ON PROSTATE CANCER
Problem Statement GOAL: To modify the needle used during a Fine Needle Aspiration (FNA) procedure. The modification should not drastically change the.
Figure 3 Semantic model of the active surveillance (AS) timeline
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Willie Underwood, III, MD, MS,MPH
Volume 66, Issue 5, Pages (November 2014)
EARLY AND LATE COMPLICATIONS OF PROSTATE LOW DOSE BRACHYTHERAPY
Tillmann Loch, Pat Fox Fulgham  European Urology 
Active Surveillance for Low Risk Prostate Cancer
Genomic Testing: When and Why
Biopsy Types Fine Needle Aspiration Core Biopsy Surgical Biopsy
ULTRASOUND NEWS
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Multigene Genomic Testing (ONCOTYPE DX)
A case of localized Prostate Cancer Marije Hamaker.
Prostate cancer screening beyond PSA – STHLM3 and/or MRI
Presentation transcript:

Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies in Awareness and Management” The Prostate Net October 6, 2009 New York, NY Angelo M. De Marzo, MD PhD The Johns Hopkins University School of Medicine, Departments of Pathology, Urology and Oncology, The Brady Urological Research Institute, The Kimmel Comprehensive Cancer Center at Johns Hopkins

What is a Pathologist? All biopsy tissue is sent to a pathologist who uses a microscope to determine the diagnosis (e.g. cancer or not)

What is a prostate biopsy? Usually 8-12 or more “cores” of tissue are taken using Transrectal Ultrasound (TRUS) guidance. Actual Prostate Core Needle Biopsies Under Microscope: Low Magnification

What if cancer is not present on biopsy? If the biopsy diagnosis is: Atypical: “Small focus of atypical gland suspicious for but not diagnostic of cancer” “Atypical small acinar proliferation” (ASAP) Up to 50% (or more) of men with a diagnosis of atypical will be found to have cancer on a repeat biopsy Most recommend a repeat biopsy High grade PIN a repeat biopsy should be based on a number of factors that you discuss with your physician

What if cancer is not present on biopsy? If biopsy is called benign: For example benign prostatic tissue; should not be called BPH Inflammation (acute or chronic) Since the biopsy sampling technique is imperfect, up to 20% (or more) of men with a negative prostate biopsy may be found to have cancer on a repeat biopsy The decision for a repeat biopsy should be based on a number of factors that you discuss with your physician

What you need to know from your prostate biopsy results if there is cancer present Gleason Grading What is the Gleason score? (two separate numbers from 1-5 added together; most common is 3+3=6) What is the number of tissue cores positive for cancer and what is the total number of tissue cores taken? Gleason Score Grade 2-6: low aggressiveness Grade 8-10: high aggressiveness Grade 7: intermediate aggressiveness

Gleason Patterns Gleason Pattern 3 Gleason Pattern 5 Microscopic appearance of prostate cancer (adenocarcinoma) under higher magnification

Active Surveillance Some patients with limited Gleason score 6 (e.g. less than 3 cores positive and no core with more than 50% cancer) elect to forego immediate treatment and undergo active surveillance A potential pitfall with this is: Up to 25% of patients with a Gleason grade 6 tumor on biopsy will be found to have a Gleason 7 or higher if their prostate is removed Researchers are attempting to find biological factors in the biopsy to help predict who will have higher grade or more aggressive disease The “good news” is that even in men who “progress” to more advanced pathology on an active surveillance program, most still have curable disease when the prostate is removed Most “progression” events occur within 2 years suggesting that undersampling, rather than disease progression, is responsible J. Urology, Vol. 181, , April 2009 J. Urology, Vol. 182, , November 2009

Discussion Topics Should I get a second opinion on my pathology slides? Should I get my prostate biopsy tissue evaluated by Aureon Laboratories Prostate Px+?